Protagenic Therapeutics Inc (NASDAQ:PTIX)
| 0.75 BATS BZX Real-Time Price As of 1:28pm ET |  -0.066 / -8.09%Today’s Change | 0.73 Today|||52-Week Range 2.52 | -53.13% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP -- |
Company Description
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.
Contact Information
Protagenic Therapeutics, Inc. 149 Fifth Avenue New York New York 10010 |
Employees
Shareholders
| Mutual fund holders | 1.34% |
| Other institutional | 0.88% |
| Individual stakeholders | -- |
Top Executives
| Andrew Slee | Chief Operating Officer |
| Alexander K. Arrow | Chief Financial Officer |
| Robert Benjamin Stein | Director & Chief Medical Officer |
| Christina Faragalla | Director-Project Management |
